Conference icon

Conference

Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study

Publication status:
Published

Actions


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Neuroscience
Haworth, J More by this author
Hendrix, S More by this author
Expand authors...
Volume:
66
Issue:
5
Pages:
A347-A347
Publication date:
2006-03-14
ISSN:
0028-3878
URN:
uuid:d94555be-f10b-490f-a97f-61f70774dbd5
Source identifiers:
39838
Local pid:
pubs:39838

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP